Medication info
Dapasingul Tablets 10 mg (Dapagliflozin Propanediol Hydrate)

Dapasingul Tablets 10 mg (Dapagliflozin Propanediol Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
CMG Pharmaceutical Co., Ltd.
Appearance
Yellow, bi-convex, diamond-shaped film-coated tablet
Packaging
PTP - 28 tablets/box [(7 tablets/PTP x 4)], bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202202088 · Approved 2022.05.18 · Insurance code 648604450

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this drug is 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received drug treatment for diabetes, the recommended initial dose of this drug when administered in combination with metformin is 5 mg once daily or 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Administration of this drug is not recommended for the purpose of improving glycemic control. - Patients on dialysis: Do not administer this drug. Hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This drug may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Ingredients

Manufacturer
CMG Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood glucose control abnormalities
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medicine is used alongside dietary management and exercise therapy to help control blood glucose levels in patients with type 2 diabetes. It can be administered alone or in combination with other medications. It is particularly beneficial for patients whose blood glucose is not adequately controlled, as well as those with or at risk for cardiovascular diseases. Clinical trials recommend consulting professional information regarding the impact of this drug on cardiovascular events. Overall, this drug is effectively used in the treatment of type 2 diabetes.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this drug is 10 mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received drug treatment for diabetes, the recommended initial dose of this drug when administered in combination with metformin is 5 mg once daily or 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Administration of this drug is not recommended for the purpose of improving glycemic control. - Patients on dialysis: Do not administer this drug. Hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This drug may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Precautions

This medicine should not be used in patients with a history of allergic reactions to the active ingredients or excipients. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. The drug contains lactose, and should not be used in patients with hereditary conditions such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption. It should also not be administered to patients undergoing renal dialysis. Use with caution in patients with reduced fluid volume or poor kidney function, as blood pressure drop or worsening kidney function may occur; the patient's condition should be monitored before and after administration. In patients with moderate to severe reduced kidney function, blood glucose control efficacy may decrease, and this medication is not recommended for patients with very low kidney function. This medication may increase the risk of genital infections and urinary tract infections, so immediate treatment is necessary upon symptoms of infection. When used with insulin or sulfonylureas, which have a risk of hypoglycemia, pay attention to symptoms of low blood sugar, and adjust the dosage of those medications if necessary. There can be signs of dehydration or hypotension due to reduced fluid volume, so caution is needed, especially in elderly patients or those taking diuretics. Diabetic ketoacidosis may occur; if symptoms such as vomiting, abdominal pain, or difficulty breathing appear, inform medical personnel immediately. Pregnant or breastfeeding women should avoid using this medicine, and if pregnancy is confirmed, discontinuation should occur. The safety and efficacy for children have not been established, and it should not be used in pediatric patients. In the event of an overdose, appropriate treatment depending on symptoms is required, and since there is no specific antidote, medical personnel's instructions should be followed. This medication does not significantly affect driving or operating machinery, but caution is necessary in cases where there is a risk of hypoglycemia.

Side effects

vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal gangrene, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, elevated hematocrit, decreased renal creatinine clearance in the early phase of treatment, dyslipidemia, elevated blood creatinine in the early phase of treatment, elevated blood urea, weight loss, acute pyelonephritis, rash, angioedema, weakness, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina, myocardial infarction, bile duct stones, cholangitis, alcoholic cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, urgency, diabetic nephropathy, overactive bladder, microalbuminuria, stress urinary incontinence, urinary hesitancy, urinary stones, abnormal urination, elevated blood lactate, lymphocytopenia, vitamin D deficiency, decreased appetite, next syndrome, dysgeusia, drowsiness, tension headache, carpal tunnel syndrome, diabetic neuropathy, unconsciousness, nerve compression, neuralgia, peripheral neuropathy, sleep disorders, fainting, tremor, bronchitis, herpes zoster, sinusitis, tonsillitis, herpes simplex, stye, joint abscess, laryngitis, otitis media, pelvic inflammatory disease, pericoronitis, pneumonia, pulmonary tuberculosis, rhinitis, toenail fungus, herpes simplex, edema, fever, foreign body sensation, facial edema, facial pain, warmth, flu-like symptoms, chest pain, fatigue, pain, edema, foreign body sensation, breast mass, erectile dysfunction, benign prostatic hyperplasia, breast pain, genital rash, menorrhagia, genital edema, uterine bleeding, vaginal bleeding, vulvar discomfort, menstrual irregularities, itching, hives, cold sweat, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, shortness of breath, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyp, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly closed container to avoid exposure to air and moisture. It is recommended to maintain storage temperature between 1 to 30 degrees Celsius. This will help preserve the effectiveness of the medication.

Appearance and packaging

Appearance

Yellow, bi-convex, diamond-shaped film-coated tablet

Package unit

PTP - 28 tablets/box [(7 tablets/PTP x 4)], bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.